Compare · AGMB vs GILD
AGMB vs GILD
Side-by-side comparison of AgomAb Therapeutics NV (AGMB) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGMB and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $161.88B, about 300.6x AGMB ($538.5M).
- Over the past year, AGMB is down 27.0% and GILD is up 22.6% - GILD leads by 49.6 points.
- GILD has been more active in the news (8 items in the past 4 weeks vs 4 for AGMB).
- GILD has more recent analyst coverage (25 ratings vs 3 for AGMB).
- Company
- AgomAb Therapeutics NV
- Gilead Sciences Inc.
- Price
- $11.11+5.81%
- $130.38-2.48%
- Market cap
- $538.5M
- $161.88B
- 1M return
- -12.79%
- -5.67%
- 1Y return
- -26.96%
- +22.62%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 1992
- News (4w)
- 4
- 8
- Recent ratings
- 3
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest AGMB
- SEC Form 6-K filed by AgomAb Therapeutics NV
- Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
- SEC Form 20-F filed by AgomAb Therapeutics NV
- SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV
- Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
- SEC Form 3 filed by new insider Bond Colin Michael
- SEC Form 3 filed by new insider Van Der Horst Paul Henryk
- SEC Form 3 filed by new insider Knotnerus Tim Jasper
- SEC Form 3 filed by new insider Borderias Andrea Saez
- SEC Form 3 filed by new insider Verduyn-Van Weegen Felice Isabel
Latest GILD
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
- SEC Form 4 filed by Dickinson Andrew D
- SEC Form 4 filed by Mercier Johanna
- PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
- Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
- EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
- Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
- Gilead Extends Tender Offer to Acquire Arcellx
- SEC Form 4 filed by O'Day Daniel Patrick